Published in Bioorg Med Chem on February 26, 2011
Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier. Mol Pharm (2013) 0.82
[¹¹C]Rhodamine-123: synthesis and biodistribution in rodents. Nucl Med Biol (2012) 0.81
Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113. Nucl Med Biol (2012) 0.81
Synthesis and evaluation of new fluorine-18 labeled verapamil analogs to investigate the function of P-glycoprotein in the blood-brain barrier. ACS Chem Neurosci (2017) 0.76
PET Tracers for Clinical Imaging of Breast Cancer. J Oncol (2012) 0.76
Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther (2001) 2.67
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol (2005) 2.43
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol (2005) 1.44
Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem (2008) 1.43
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med (2010) 1.16
(R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol (2003) 1.11
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Evaluation of limiting brain penetration related to P-glycoprotein and breast cancer resistance protein using [(11)C]GF120918 by PET in mice. Mol Imaging Biol (2011) 1.06
Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol (2009) 1.02
Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication. J Med Chem (2010) 0.96
Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. J Med Chem (2009) 0.94
Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem (2007) 0.91
Synthesis and in vivo evaluation of ¹⁸F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters. Bioorg Med Chem (2010) 0.90
Comparison of drug efflux transport kinetics in various blood-brain barrier models. Drug Metab Dispos (2006) 0.85
A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier. Pharm Res (2005) 0.84
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nucl Med Biol (2010) 0.81
Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice. Nucl Med Biol (2010) 0.80
pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics (2011) 16.75
Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One (2010) 6.38
The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem Int Ed Engl (2011) 4.39
Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell (2013) 4.16
SuperHirn - a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics (2007) 3.60
Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl (2010) 3.50
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis (2013) 3.46
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med (2008) 3.28
The neurobiology of antiepileptic drugs. Nat Rev Neurosci (2004) 3.24
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res (2007) 3.04
An integrated mass spectrometric and computational framework for the analysis of protein interaction networks. Nat Biotechnol (2007) 2.59
Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein bassoon. Neuron (2003) 2.31
Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. J Neurol Sci (2012) 1.97
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med (2004) 1.89
Seizure recurrence after planned discontinuation of antiepileptic drugs in seizure-free patients after epilepsy surgery: a review of current clinical experience. Epilepsia (2004) 1.87
Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia (2005) 1.86
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol (2013) 1.82
High resolution PTR-TOF: quantification and formula confirmation of VOC in real time. J Am Soc Mass Spectrom (2010) 1.72
Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc (2006) 1.68
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med (2005) 1.67
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging (2004) 1.67
Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther (2003) 1.61
Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? Expert Rev Proteomics (2009) 1.61
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia (2007) 1.55
Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology (2011) 1.53
Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. Am J Hum Genet (2010) 1.52
Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging (2014) 1.49
Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users. Ann Thorac Surg (2011) 1.49
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology (2008) 1.48
An open-system quantum simulator with trapped ions. Nature (2011) 1.46
In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem Biophys Res Commun (2009) 1.45
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 1.44
Processing and classification of protein mass spectra. Mass Spectrom Rev (2006) 1.42
Anticonvulsant effects of transcranial direct-current stimulation (tDCS) in the rat cortical ramp model of focal epilepsy. Epilepsia (2006) 1.41
Search strategies-identified reports on "off-label" drug use in MEDLINE. J Clin Epidemiol (2012) 1.41
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol (2012) 1.41
Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice. Exp Neurol (2007) 1.40
Automated protein identification by tandem mass spectrometry: issues and strategies. Mass Spectrom Rev (2006) 1.40
Quantitative proteomic analysis of protein complexes: concurrent identification of interactors and their state of phosphorylation. Mol Cell Proteomics (2007) 1.38
Ethanol-induced activation of myosin light chain kinase leads to dysfunction of tight junctions and blood-brain barrier compromise. Alcohol Clin Exp Res (2005) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP. Biochemistry (2007) 1.35
Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem (2004) 1.35
Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angew Chem Int Ed Engl (2012) 1.34
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis (2006) 1.33
Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain (2011) 1.33
Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther (2011) 1.33
Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors. Int J Cancer (2012) 1.30
Dissociable network properties of anesthetic state transitions. Anesthesiology (2011) 1.29
Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci (2010) 1.29
Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging (2007) 1.25
Quantum Google in a complex network. Sci Rep (2013) 1.24
The SYBR Green I malaria drug sensitivity assay: performance in low parasitemia samples. Am J Trop Med Hyg (2010) 1.24
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev (2003) 1.22
Remodeling the regulation of iron metabolism during erythroid differentiation to ensure efficient heme biosynthesis. Blood (2006) 1.21
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis (2009) 1.20
EasyProt--an easy-to-use graphical platform for proteomics data analysis. J Proteomics (2012) 1.20
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther (2005) 1.19
The vineyard yeast microbiome, a mixed model microbial map. PLoS One (2012) 1.18
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology (2006) 1.18
Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol (2006) 1.18
Mutation in the Scyl1 gene encoding amino-terminal kinase-like protein causes a recessive form of spinocerebellar neurodegeneration. EMBO Rep (2007) 1.18
Multimodality rodent imaging chambers for use under barrier conditions with gas anesthesia. Mol Imaging Biol (2008) 1.17
Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res (2003) 1.17
Detection of plant volatiles after leaf wounding and darkening by proton transfer reaction "time-of-flight" mass spectrometry (PTR-TOF). PLoS One (2011) 1.15
Parallel isotope-based quantification of modified tRNA nucleosides. Angew Chem Int Ed Engl (2009) 1.14
Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther (2003) 1.14
pH dependence of melanoma cell migration: protons extruded by NHE1 dominate protons of the bulk solution. J Physiol (2007) 1.13